PureTech Health, Johnson & Johnson and Novartis are in line for exits after the cancer drug developer filed for its initial public offering.

The immunotherapy developer plans to go public in the United States having raised $565m from investors including Eli Lilly and WuXi AppTec.

Cambrian Biopharma is the largest investor in cancer immunotherapy developer Sensei Biotherapeutics, which has filed to raise up to $100m.

Novo and existing backer GV participated in a round that lifted the heart disease drug developer's overall funding to more than $215m.

University of Washington spinout AltPep will use the proceeds from the Alexandria Venture Investments-backed round to advance a lead asset targeting Alzheimer’s disease.

Biohaven has purchased the 58% stake cancer immunotherapy developer Kleo Pharmaceuticals it did not already own.

The Anthem and Comcast-backed remote healthcare provider doubled its valuation for the second time in 10 months, in a series E round valuing it at $1.5bn.

HealthQuest Capital supplied $75m for the medical test provider, which counts The Chernin Group as an investor, at a flat $1.3bn valuation.

UPMC-backed cancer immunotherapy developer BlueSphere Bio has attracted an initial $45.6m in series B funding towards a $105m target for its close.

Fidelity provided a $4.8m second tranche after a first close featuring vehicles for Kyushu University and Osaka University.